Literature DB >> 15179559

Down-regulation of Bcl-2 in the fetal brain of the Gaucher disease mouse model: a possible role in the neuronal loss.

Young Bin Hong1, Eun Young Kim1, Sung-Chul Jung2.   

Abstract

Gaucher disease is a lysosomal storage disorder resulting from an inborn deficiency of glucocerebrosidase. To investigate the genes responsible for the neuronal symptoms of Gaucher disease, gene expression profiles were analyzed in brains of the Gaucher disease mouse model using a cDNA microarray, and it was found that the bcl-2 gene is down-regulated. Immunoblotting and apoptosis assay were performed to study the relationship between the decreased expression of Bcl-2 and neuronal death on the brains of Gaucher mice fetuses at embryonic day 17.5 (E17.5) and E19.5. Decreased expression of Bcl-2 was observed in the brain stem and cerebellum but not in cortex by immunoblotting. In situ labeling of DNA fragmentation using terminal transferase-mediated dUTP nick-end-labeling (TUNEL) assay confirmed that apoptosis occurred in the brain stem and cerebellum. More apoptotic cells were detected in the brains of Gaucher mice fetuses at E19.5 than at E17.5. These results suggest that the accumulation of either glucocerebroside or glucosylsphingosine, as a result of glucocerebrosidase deficiency, affects gene expression and could be responsible for neuronal cell death.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15179559     DOI: 10.1007/s10038-004-0155-2

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  18 in total

1.  Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene.

Authors:  V L Tybulewicz; M L Tremblay; M E LaMarca; R Willemsen; B K Stubblefield; S Winfield; B Zablocka; E Sidransky; B M Martin; S P Huang
Journal:  Nature       Date:  1992-06-04       Impact factor: 49.962

2.  The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase.

Authors:  D Pelled; H Shogomori; A H Futerman
Journal:  J Inherit Metab Dis       Date:  2000-03       Impact factor: 4.982

3.  Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation.

Authors:  E Orvisky; E Sidransky; C E McKinney; M E Lamarca; R Samimi; D Krasnewich; B M Martin; E I Ginns
Journal:  Pediatr Res       Date:  2000-08       Impact factor: 3.756

4.  Inactivation of bcl-2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development.

Authors:  T M Michaelidis; M Sendtner; J D Cooper; M S Airaksinen; B Holtmann; M Meyer; H Thoenen
Journal:  Neuron       Date:  1996-07       Impact factor: 17.173

5.  Inhibition of cytochrome c oxidase and hemolysis caused by lysosphingolipids.

Authors:  H Igisu; N Hamasaki; A Ito; W Ou
Journal:  Lipids       Date:  1988-04       Impact factor: 1.880

6.  Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses.

Authors:  Y A Hannun; R M Bell
Journal:  Science       Date:  1987-02-06       Impact factor: 47.728

7.  Lyso-glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms.

Authors:  Emyr Lloyd-Evans; Dori Pelled; Christian Riebeling; Anthony H Futerman
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

8.  Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3.

Authors:  U H Schueler; T Kolter; C R Kaneski; J K Blusztajn; M Herkenham; K Sandhoff; R O Brady
Journal:  Neurobiol Dis       Date:  2003-12       Impact factor: 5.996

9.  Suppression of bcl-2 gene expression by sphingosine in the apoptosis of human leukemic HL-60 cells during phorbol ester-induced terminal differentiation.

Authors:  C Sakakura; E A Sweeney; T Shirahama; S Hakomori; Y Igarashi
Journal:  FEBS Lett       Date:  1996-01-29       Impact factor: 4.124

10.  Type 2 and type 3 Gaucher disease: a morphological and biochemical study.

Authors:  E M Kaye; M D Ullman; E R Wilson; J A Barranger
Journal:  Ann Neurol       Date:  1986-08       Impact factor: 10.422

View more
  9 in total

Review 1.  Glycosphingolipidoses: beyond the enzymatic defect.

Authors:  Annick Raas-Rothschild; Irene Pankova-Kholmyansky; Yaacov Kacher; Anthony H Futerman
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

2.  Global gene expression profile progression in Gaucher disease mouse models.

Authors:  You-Hai Xu; Li Jia; Brian Quinn; Matthew Zamzow; Keith Stringer; Bruce Aronow; Ying Sun; Wujuan Zhang; Kenneth D R Setchell; Gregory A Grabowski
Journal:  BMC Genomics       Date:  2011-01-11       Impact factor: 3.969

3.  Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model.

Authors:  Nupur Dasgupta; You-Hai Xu; Ronghua Li; Yanyan Peng; Manoj K Pandey; Stuart L Tinch; Benjamin Liou; Venette Inskeep; Wujuan Zhang; Kenneth D R Setchell; Mehdi Keddache; Gregory A Grabowski; Ying Sun
Journal:  Hum Mol Genet       Date:  2015-09-29       Impact factor: 6.150

4.  Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse.

Authors:  Young Bin Hong; Eun Young Kim; Sung-Chul Jung
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

Review 5.  Animal models for Gaucher disease research.

Authors:  Tamar Farfel-Becker; Einat B Vitner; Anthony H Futerman
Journal:  Dis Model Mech       Date:  2011-10-04       Impact factor: 5.758

6.  Gaucher disease: transcriptome analyses using microarray or mRNA sequencing in a Gba1 mutant mouse model treated with velaglucerase alfa or imiglucerase.

Authors:  Nupur Dasgupta; You-Hai Xu; Sunghee Oh; Ying Sun; Li Jia; Mehdi Keddache; Gregory A Grabowski
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

Review 7.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Fabrice Camou; Christine Serratrice; Roseline Froissart; Catherine Caillaud; Thierry Levade; Leonardo Astudillo; Jacques Serratrice; Anaïs Brassier; Christian Rose; Thierry Billette de Villemeur; Marc G Berger
Journal:  Int J Mol Sci       Date:  2017-02-17       Impact factor: 5.923

8.  Gene expression profile in patients with Gaucher disease indicates activation of inflammatory processes.

Authors:  Agnieszka Ługowska; Katarzyna Hetmańczyk-Sawicka; Roksana Iwanicka-Nowicka; Anna Fogtman; Jarosław Cieśla; Joanna Karolina Purzycka-Olewiecka; Dominika Sitarska; Rafał Płoski; Mirella Filocamo; Susanna Lualdi; Małgorzata Bednarska-Makaruk; Marta Koblowska
Journal:  Sci Rep       Date:  2019-04-15       Impact factor: 4.379

Review 9.  Induced Pluripotent Stem Cell Modeling of Gaucher's Disease: What Have We Learned?

Authors:  Dino Matias Santos; Gustavo Tiscornia
Journal:  Int J Mol Sci       Date:  2017-04-21       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.